ABBV stock forecast, quote, news & analysis

Key Takeaways

• AbbVie shares traded near $257 in mid-September 2026, up roughly 3% over the prior 30 days after ranging between about $243 and $267.
• Second-quarter 2026 revenue rose 10.2% to $16.99 billion, beating consensus estimates, with adjusted earnings of $3.65 per share.
• Skyrizi and Rinvoq remain the core growth engines, climbing 24% and 23.7% operationally, more than offsetting Humira's biosimilar-driven decline.
• Management raised full-year revenue guidance to about $67.6 billion, while the planned Apogee Therapeutics acquisition trimmed the adjusted EPS outlook to $13.87–$14.07.
• Analyst sentiment stays constructive, with a Buy-leaning consensus and an average price target near $276 following a series of recent target increases.

Current Market Snapshot

AbbVie has traded in a relatively contained band in recent weeks, with shares holding near the upper end of a roughly $243–$267 range established over the past month. The stock has posted a modest gain of about 3% over the trailing 30 days, a move that reflects steady investor appetite for large-cap biopharma rather than a sharp single-event repricing. AbbVie's valuation has also been a talking point: the shares have traded at a forward price-to-earnings multiple in the mid-teens, a discount to many large-cap peers, which several analysts have cited as a source of support. As a long-standing dividend grower, AbbVie continues to attract income-oriented investors alongside those focused on its immunology franchise.

AbbVie (ABBV) Business Overview and Competitive Position

AbbVie is a diversified, research-based biopharmaceutical company that was spun off from Abbott Laboratories in 2013. Its portfolio spans four primary areas: immunology, oncology, neuroscience, and aesthetics. The immunology franchise is the company's largest growth driver, led by Skyrizi (risankizumab), an IL-23 inhibitor, and Rinvoq (upadacitinib), an oral JAK inhibitor, which together now account for roughly half of total revenue. The neuroscience business is built around Vraylar, Botox Therapeutic, and the migraine therapies Ubrelvy and Qulipta, while oncology features Venclexta and Elahere. The aesthetics portfolio, anchored by Botox Cosmetic and Juvederm, was added through the 2020 acquisition of Allergan. AbbVie's competitive strengths include deep commercial infrastructure, a broad late-stage pipeline, and a track record of returning capital to shareholders.

Recent Developments Driving ABBV

AbbVie's second-quarter results, reported in late July, reinforced the core investment thesis. Net revenues reached $16.99 billion, up 10.2% year over year, while adjusted EPS of $3.65 rose 22.9%. Skyrizi generated $5.51 billion and Rinvoq $2.53 billion, while Humira declined 36.1% operationally to $756 million under biosimilar pressure. Neuroscience revenue grew about 20% operationally, while oncology and aesthetics were softer. Management raised full-year revenue guidance by $300 million to approximately $67.6 billion but lowered adjusted EPS guidance to $13.87–$14.07 to account for expected dilution from the roughly $10.9 billion Apogee Therapeutics acquisition, which is expected to close in the third quarter and adds long-acting immunology candidates for dermatology and respiratory disease.

Regulatory momentum has also been notable. The European Commission approved Rinvoq for non-segmental vitiligo and severe alopecia areata, with U.S. decisions anticipated in the coming quarters. Wall Street has responded favorably, with a series of price-target increases and at least one upgrade during the period, including revisions from firms such as Piper Sandler, Morgan Stanley, and HSBC. Attention now turns to a U.S. decision on a subcutaneous induction regimen for Skyrizi in Crohn's disease, expected in the fall.

Trending AI Robots

For traders looking to complement their own analysis, Tickeron's Trending AI Robots page offers a curated view of the platform's AI-driven trading tools. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are highlighted in this dedicated section. These bots vary widely in strategy, timeframe, and performance metrics, giving users a way to compare approaches that range from short-term momentum to longer-horizon trend following. The curated format is designed to help investors quickly surface the strategies that are currently generating the most attention. Exploring the section can be a useful starting point for those interested in integrating algorithmic insights into their research process.

2026 Outlook and What Investors Should Watch

Several catalysts will shape AbbVie's trajectory through the remainder of 2026. The completion of the Apogee Therapeutics acquisition and the advancement of its lead asset, the long-acting anti-IL-13 candidate zumilokibart, are central to the company's efforts to extend immunology growth into the 2030s. Investors are also watching the expected U.S. regulatory decision on Skyrizi's subcutaneous induction for Crohn's disease, plus late-stage data in hidradenitis suppurativa for Rinvoq and lutikizumab. U.S. decisions on Rinvoq for vitiligo and alopecia areata represent additional near-term opportunities.

On the risk side, ongoing Humira biosimilar erosion, Inflation Reduction Act-related pricing pressure on oncology products such as Imbruvica, and softness in aesthetics remain key watch items. Competitive dynamics in immunology also warrant monitoring, with peers such as Johnson & Johnson and Eli Lilly investing heavily in next-generation therapies. Macroeconomic conditions, including interest-rate policy and drug-pricing regulation, could further influence sentiment across the pharmaceutical sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations